Developability Assessment

Aragen’s Developability Package for antibodies and other protein therapeutics allows you to make crucial data-driven decisions to select the final variant to advance as your clinical candidate. Molecules that are suitable for short-term Phase I studies at low doses can have hidden liabilities that may not present until later in clinical development when the cost of failure is high.

In addition to confirmation of sequence and post-translational modifications, Aragen’s Developability Package combines in silico methods and experimental data to identify, assess and mitigate potential problems including:

  • Instability
  • Limited solubility
  • Unwanted stress-induced post-translational modifications
  • Aggregation formation during manufacturing, formulation and storage
Developability FlyerDownload CollateralQuote Request

Aragen’s analytical platforms are used during developability assessments and continued throughout cell line development enabling smoother tech transfers to GMP manufacturing by identifying and tracking Critical Quality Attributes from the start. Contact us or download our flyer and developability presentation today.